{"nctId":"NCT00316277","briefTitle":"Prescription Opioid Addiction Treatment Study (POATS)","startDateStruct":{"date":"2006-05"},"conditions":["Opiate Dependence","Substance-related Disorders","Opioid-related Disorders"],"count":653,"armGroups":[{"label":"Buprenorphine/Nx with EMM","type":"EXPERIMENTAL","interventionNames":["Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse"]},{"label":"Buprenorphine/Nx with SMM","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse"]}],"interventions":[{"name":"Standard Medical Management (SMM) of Prescription Opiate Abuse","otherNames":[]},{"name":"Enhanced Medical Management (EMM) of Prescription Opiate Abuse","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years old or older\n* Physically dependent on opioids\n* Meet DSM-IV criteria for opioid dependence\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to buprenorphine or naloxone\n* Unstable psychiatric disorder\n* Pregnant or lactating females\n* Liver function test results greater than 5 times the upper limit of normal range","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1","description":"In Phase 1, successful outcome was defined as completing week 12 with self-reported opioid use on no more than 4 days in a month, absence of 2 consecutive opioid-positive urine test results, no additional substance use disorder treatment (other than self-help), and no more than 1 missing urine sample during the 12 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition Phase 2, 8-week Posttreatment Follow-up","description":"A planned secondary outcome, successful outcome at week 24, that is, 8 weeks after completion of buprenorphine-naloxone taper, was defined the same as at week 12 of Phase 2, that is abstinent from opioids during week 24 and at least 2 of the previous 3 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Attaining Successful Opioid Use Outcomes in Phase 1 by Chronic Pain Condition","description":"As a planned secondary analysis, we examined the impact of the two Phase 1 stratification variables on the primary end points. Patients were designated at baseline as having current chronic pain if they reported pain \"other than everyday kinds of pain\" excluding withdrawal-related pain, for at least 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Attaining Successful Opioid Use Outcomes in Phase 2 by Chronic Pain Condition","description":"As a planned secondary analysis, we examined the impact of the two Phase 1 stratification variables on the primary end points. Patients were designated at baseline as having current chronic pain if they reported pain \"other than everyday kinds of pain\" excluding withdrawal-related pain, for at least 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With and Without Any Lifetime Use of Heroin Attaining Successful Opioid Use Outcomes in Phase 1","description":"As a planned secondary analysis, we examined the impact of the two phase 1 stratification variables on the primary outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With and Without Any Lifetime Use of Heroin Attaining Successful Opioid Use Outcomes in Phase 2","description":"As a planned secondary analysis, we examined the impact of the two phase 1 stratification variables on the primary outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition, Phase 2 End of Treatment","description":"In phase 2, successful outcome was defined as abstaining from opioids during week 12 (the final week of buprenorphine-naloxone stabilization) and during at least 2 of the previous 3 weeks (weeks 9-11). This outcome measure required substantial improvement but not complete abstinence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":329},"commonTop":["Headache","Constipation","Insomnia","Nausea","Vomiting"]}}}